Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of Cisplatin Nephrotoxicity in Cancer Patients
NCT07874373Completed
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
- Start
- Mar 2021
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Randomised, open-label trial of magnesium sulfate in cisplatin-induced nephrotoxicity (CIN) (2 arms), sponsored by Grigore T. Popa University of Medicine and Pharmacy. Primary endpoint: Incidence of Early Cisplatin-Associated Renal Toxicity at 48 hours. Started Mar 2021; status: completed.
02
Drugs
magnesium sulfate
03
Conditions
cisplatin-induced nephrotoxicity (CIN)
Beyond the preview
Go deeper on NCT07874373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07874373.